These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 11816707

  • 1. Imbalance of plasminogen activator inhibitor-I/ tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction.
    Saigo M, Abe S, Ogawa M, Yamashita T, Biro S, Minagoe S, Maruyama I, Tei C.
    Thromb Haemost; 2001 Nov; 86(5):1197-203. PubMed ID: 11816707
    [Abstract] [Full Text] [Related]

  • 2. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C.
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [Abstract] [Full Text] [Related]

  • 3. Plasma thrombomodulin activity, tissue factor activity and high levels of circulating procoagulant phospholipid as prognostic factors for acute myocardial infarction.
    Van Dreden P, Rousseau A, Savoure A, Lenormand B, Fontaine S, Vasse M.
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):635-41. PubMed ID: 19809306
    [Abstract] [Full Text] [Related]

  • 4. Plasminogen activator inhibitor 1 is elevated in the children of men with premature myocardial infarction.
    Rallidis LS, Megalou AA, Papageorgakis NH, Trikas AG, Chatzidimitriou GI, Tsitouris GK.
    Thromb Haemost; 1996 Sep; 76(3):417-21. PubMed ID: 8883280
    [Abstract] [Full Text] [Related]

  • 5. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
    Sebestjen M, Zegura B, Guzic-Salobir B, Keber I.
    Wien Klin Wochenschr; 2001 Feb 15; 113(3-4):113-8. PubMed ID: 11253736
    [Abstract] [Full Text] [Related]

  • 6. The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project.
    Nordenhem A, Leander K, Hallqvist J, de Faire U, Sten-Linder M, Wiman B.
    Thromb Res; 2005 Feb 15; 116(3):223-32. PubMed ID: 15935831
    [Abstract] [Full Text] [Related]

  • 7. Low level of tissue plasminogen activator activity in non-diabetic patients with a first myocardial infarction.
    Lundblad D, Dinesen B, Rautio A, Røder ME, Eliasson M.
    J Intern Med; 2005 Jul 15; 258(1):13-20. PubMed ID: 15953128
    [Abstract] [Full Text] [Related]

  • 8. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
    Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG.
    Thromb Haemost; 1998 Mar 15; 79(3):495-9. PubMed ID: 9531029
    [Abstract] [Full Text] [Related]

  • 9. [Value of plasma tissue factor, tissue factor pathway inhibitor and factor VII assessments in patients with acute myocardial and cerebral infarction].
    Xiong SL, Wang Q, Zheng L, Li JL, Wen ZB, He SL.
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Dec 15; 27(12):1821-3. PubMed ID: 18158992
    [Abstract] [Full Text] [Related]

  • 10. Changes in plasma C-reactive protein and hemostatic factors prior to and after a first myocardial infarction with a median follow-up time of 8 years.
    Thøgersen AM, Nilsson TK, Weinehall L, Boman K, Eliasson M, Hallmans G, Jansson JH.
    Blood Coagul Fibrinolysis; 2009 Jul 15; 20(5):340-6. PubMed ID: 19357504
    [Abstract] [Full Text] [Related]

  • 11. High prevalence of metabolic syndrome among young women with nonfatal myocardial infarction.
    Amowitz LL, Ridker PM, Rifai N, Loughrey CM, Komaroff AL.
    J Womens Health (Larchmt); 2004 Mar 15; 13(2):165-75; discussion 175. PubMed ID: 15072730
    [Abstract] [Full Text] [Related]

  • 12. Relationship of tissue plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen with coronary artery disease in South Indian male subjects.
    Deepa R, Velmurugan K, Saravanan G, Dwarakanath V, Agarwal S, Mohan V.
    J Assoc Physicians India; 2002 Jul 15; 50():901-6. PubMed ID: 12126344
    [Abstract] [Full Text] [Related]

  • 13. Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus.
    Ludwig S, Dharmalingam S, Erickson-Nesmith S, Ren S, Zhu F, Ma GM, Zhao R, Fenton JW, Ofosu FA, Velthuis HT, van Mierlo G, Shen GX.
    Diabetes Res Clin Pract; 2005 Nov 15; 70(2):110-8. PubMed ID: 16188573
    [Abstract] [Full Text] [Related]

  • 14. Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients.
    Pawlak K, Mysliwiec M, Pawlak D.
    Thromb Res; 2010 Feb 15; 125(2):e40-5. PubMed ID: 19732942
    [Abstract] [Full Text] [Related]

  • 15. Physiological testosterone stimulates tissue plasminogen activator and tissue factor pathway inhibitor and inhibits plasminogen activator inhibitor type 1 release in endothelial cells.
    Jin H, Lin J, Fu L, Mei YF, Peng G, Tan X, Wang DM, Wang W, Li YG.
    Biochem Cell Biol; 2007 Apr 15; 85(2):246-51. PubMed ID: 17534406
    [Abstract] [Full Text] [Related]

  • 16. Tissue factor pathway inhibitor, natural coagulation inhibitors and hemostatic activation markers in patients with acute coronary syndromes.
    Al-Nozha MM, Abdel-Gader AG, Arafah MR, Al-Maatouq MA, Al-Shahid MS, Al-Harthi SS, Khan NB, Abdullah MA.
    Saudi Med J; 2005 Jun 15; 26(6):937-42. PubMed ID: 15983678
    [Abstract] [Full Text] [Related]

  • 17. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
    Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U.
    Arterioscler Thromb Vasc Biol; 2000 Aug 15; 20(8):2019-23. PubMed ID: 10938026
    [Abstract] [Full Text] [Related]

  • 18. Lower tissue factor inhibition in patients with ST segment elevation than in patients with non ST elevation acute myocardial infarction.
    Figueras J, Monasterio J, Lidón RM, Sambola A, Garcia-Dorado D.
    Thromb Res; 2012 Sep 15; 130(3):458-62. PubMed ID: 22424853
    [Abstract] [Full Text] [Related]

  • 19. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
    Makris TK, Stavroulakis G, Papadopoulos DP, Krespi P, Hatzizacharias A, Zilidis A, Tsoukala C, Votteas VE.
    Drugs Exp Clin Res; 2004 Sep 15; 30(3):125-32. PubMed ID: 15366789
    [Abstract] [Full Text] [Related]

  • 20. Haemostatic risk factors for cardiovascular diseases.
    Koenig W.
    Eur Heart J; 1998 Apr 15; 19 Suppl C():C39-43. PubMed ID: 9597424
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.